
Delcath Systems (DCTH) Stock Forecast & Price Target
Delcath Systems (DCTH) Analyst Ratings
Bulls say
Delcath Systems Inc. is actively expanding its treatment centers and anticipates positive data from clinical trials, which could enhance the adoption of its Melphalan Hydrochloride for Injection product and related delivery system. The company is projecting growth in its total revenues to $343 million by 2032 and expects improvements in margins to offset a slight reduction in revenue projections, indicating strong operational management and strategic foresight. Additionally, with the anticipated publication of the CHOPIN trial data and ongoing site activations, there is a positive trajectory for the establishment of Hepzato in the U.S. market, suggesting solid growth potential despite pricing adjustments.
Bears say
Delcath Systems Inc. faces significant headwinds, with preliminary third-quarter 2025 revenues reported at $20.5 million, marking a 15% decline from the previous quarter and falling short of consensus estimates. The company has revised its full-year revenue guidance down to $83 million to $85 million from an earlier projection of $93 million to $96 million, reflecting challenges such as slowed site activations and seasonal impacts on patient starts. Furthermore, the anticipated decrease in average revenue per kit due to the Medicaid National Drug Rebate Agreement Program adds to the financial pressures, warranting a cautious outlook on the company's future revenue performance.
This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.
Delcath Systems (DCTH) Analyst Forecast & Price Prediction
Start investing in Delcath Systems (DCTH)
Order type
Buy in
Order amount
Est. shares
0 shares